Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06523517
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-18
Brief Title:
Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-center Single-arm Prospective Clinical Study to Evaluate the Efficacy and Safety of Eliglustat in Chinese Pediatric Patients 12 to 18 Years Old With Gaucher Disease Type 1 and Type 3
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Objective
Evaluate the efficacy and safety of eliglustat in Chinese pediatric patients 12 to 18 years old with Gaucher disease type 1 and type 3
Secondary Objective
Evaluate the quality of life in Chinese pediatric patients 12 to 18 years old with Gaucher disease type 1 and type 3 treated with eliglustat
Evaluate the efficacy and safety of eliglustat in Chinese pediatric patients 12 to 18 years old with Gaucher disease type 1 and type 3
Secondary Objective
Evaluate the quality of life in Chinese pediatric patients 12 to 18 years old with Gaucher disease type 1 and type 3 treated with eliglustat
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None